We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Powered Blood Test Enables Detection, Analysis and Profiling of Cancer Tumors

By LabMedica International staff writers
Posted on 10 Dec 2024
Print article
Image: The new method will help guide cancer treatment using blood samples (Photo courtesy of 123RF)
Image: The new method will help guide cancer treatment using blood samples (Photo courtesy of 123RF)

Mutational signatures are changes in DNA patterns caused by cancer’s effects on cells in the body. These signatures can provide valuable insights into the cancer, such as the potential causes behind its development and which therapies may be most effective. Currently, obtaining this information requires whole genome sequencing of a tissue biopsy from the cancer, which is then compared to the patient's matched normal DNA sample. A standard biopsy that involves removing tissue or cells is costly and time-consuming, and it can also be difficult to collect tissue biopsy samples, especially when the tumor is located in hard-to-reach areas.

Researchers at Peter MacCallum Cancer Centre (Victoria, Australia) have now developed a method that utilizes circulating tumor DNA (ctDNA) from a patient's blood to detect cancer-related DNA changes. Their innovative approach, known as MisMatchFinder, uses an algorithm to identify these changes through a simple blood test. This method, published in Nature Communications, offers the potential to make genome sequencing more accessible and efficient, enabling quicker, personalized treatment plans for cancer patients. Moreover, it could revolutionize cancer monitoring by tracking changes in the disease over time, eliminating the need for repeated biopsies.

“Excitingly, this new methodology will allow us to observe what is happening to the tumor over various time points,” said study co-author Dr. Dineika Chandrananda. “MisMatchFinder brings considerable advances to the clinic and holds the potential to provide new insights into the use of mutational signatures. We believe that this knowledge will help guide and inform clinical decisions to optimize research led cancer treatment strategies.”

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.